Nitrobenzenes

AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Retrieved on: 
Monday, June 7, 2021
Anthelmintics, Chloroarenes, Niclosamide, Nitrobenzenes, Pesticides, Salicylanilides, Chemical substances, Chemistry, Draft:Sunshine Biopharma

FW-1022 is a proprietary oral tablet formulation of micronized niclosamide developed for the treatment of COVID-19-related GI infections.

Key Points: 
  • FW-1022 is a proprietary oral tablet formulation of micronized niclosamide developed for the treatment of COVID-19-related GI infections.
  • Dosing the first patient in the RESERVOIR clinical trial marks a significant milestone for AzurRx and the development of niclosamide as a potential treatment for COVID-19-related GI infections, said James Sapirstein, Chief Executive Officer of AzurRx BioPharma.
  • The RESERVOIR clinical trial is designed as a two-part, two-arm, placebo-controlled Phase 2 study.
  • AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

Hyundai Bioscience leads in the repurposing of Niclosamide

Retrieved on: 
Thursday, April 8, 2021
Anthelmintics, Chloroarenes, Salicylanilides, Niclosamide, Nitrobenzenes, Pesticides, Hyundai Motor Company, Drug repositioning, Repurposing, Articles, Drugs, Health sciences

CNPharm also filed international patent applications on this DDS technology for repurposing Niclosamide as COVID-19 treatment.

Key Points: 
  • CNPharm also filed international patent applications on this DDS technology for repurposing Niclosamide as COVID-19 treatment.
  • This means that the international pharmaceutical community has recognized that CNPharm, the parent company of Hyundai Bioscience, is leading the way to repurpose the anthelmintic drug.
  • An official at Hyundai Bioscience stated that this is the first time that Niclosamide's bioavailability improvement for drug repurposing has been published in an international journal.
  • Based on CNPharm's original technology, Hyundai Bioscience has dramatically improved the absorption rate and half-life of Niclosamide last year, developing CP-COV03, an oral treatment for COVID-19.

AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Retrieved on: 
Tuesday, April 6, 2021
Anthelmintics, Chloroarenes, Niclosamide, Nitrobenzenes, Pesticides, Salicylanilides, Severe acute respiratory syndrome coronavirus, COVID-19, Health, Medical specialties

These long term observation data could indicate that niclosamide treatment has the potential to improve long haul COVID-19 symptoms.

Key Points: 
  • These long term observation data could indicate that niclosamide treatment has the potential to improve long haul COVID-19 symptoms.
  • We look forward to testing this hypothesis in the RESERVOIR Phase 2 trial and reporting topline data from the trial in early 2022.
  • FW-1022 is a niclosamide based small molecule which the Companys clinical trials may establish has anti-viral activity that is effective for the treatment of SARS-CoV-2 (COVID-19) gastrointestinal infections.
  • AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections

Retrieved on: 
Tuesday, February 9, 2021
Anthelmintics, Chloroarenes, Niclosamide, Nitrobenzenes, Pesticides, Salicylanilides, Health, Coronavirus disease, Articles

Under the terms of the agreement, PPD will manage the Phase 2 clinical trial for an immediate-release capsule formulation of micronized oral niclosamide, also known as FW-1022.

Key Points: 
  • Under the terms of the agreement, PPD will manage the Phase 2 clinical trial for an immediate-release capsule formulation of micronized oral niclosamide, also known as FW-1022.
  • Licensed by AzurRx in January from FirstWave Bio, Inc., the goal of AzurRxs FW-1022 clinical program is to develop a safe, effective, non-systemic treatment for GI infections related to COVID-19.
  • FW-1022 is a niclosamide based small molecule which the Companys clinical trials may establish has anti-viral activity that is effective for the treatment of SARS-CoV-2 (COVID-19) gastrointestinal infections.
  • AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical companyspecializingin the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases.

AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections

Retrieved on: 
Tuesday, January 12, 2021
Anthelmintics, Chloroarenes, Niclosamide, Nitrobenzenes, Pesticides, Salicylanilides

AzurRx anticipates initiating a Phase 2 trial of oral niclosamide, also called FW-1022, in patients with COVID-19, in the first half of 2021.

Key Points: 
  • AzurRx anticipates initiating a Phase 2 trial of oral niclosamide, also called FW-1022, in patients with COVID-19, in the first half of 2021.
  • We are greatly encouraged by the allowance of the patent application, said James Sapirstein, President and CEO of AzurRx BioPharma.
  • Mr. Sapirstein continued, We believe that there is both a significant unmet clinical need in treating COVID-19 GI infections and a substantial untapped market opportunity.
  • AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical companyspecializingin the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases.

AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections

Retrieved on: 
Monday, January 4, 2021
Health sciences, Medical specialties, Health, Dosage forms, Routes of administration, Gastroenterology, Niclosamide, Nitrobenzenes, Salicylanilides, Enema, Modified-release dosage

We believe these niclosamide formulations could offer significant advantages over other currently available treatments.

Key Points: 
  • We believe these niclosamide formulations could offer significant advantages over other currently available treatments.
  • They are not systemically absorbed, potentially allowing for higher local GI concentrations of drug delivery and avoiding steroid-related immunosuppressant complications.
  • Mr. Sapirstein continued, With these new assets, combined with our current pipeline, we believe 2021 will be a very exciting and transformational year for AzurRx.
  • Under the terms of the agreement, AzurRx is granted a worldwide, exclusive right to develop, manufacture, and commercialize First Waves proprietary immediate release oral and enema formulations of niclosamide for the treatment of ICI-AC and COVID-19 GI infections.

Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem

Retrieved on: 
Tuesday, December 8, 2020
Chloroarenes, Anthelmintics, Niclosamide, Nitrobenzenes, Pesticides, Salicylanilides, Hyundai Motor Company, Bioavailability, Life sciences, Chemistry, Automotive industry

CP-COV03 is a Niclosamide-based modified oral drug developed by CNPharm, a bio tech company holding major shares of Hyundai Bioscience.

Key Points: 
  • CP-COV03 is a Niclosamide-based modified oral drug developed by CNPharm, a bio tech company holding major shares of Hyundai Bioscience.
  • After the efficacy testing, Hyundai Bioscience plans to go for phase 2 clinical trials and then apply for emergency use approval.
  • However, Niclosamide's low bioavailability and poor inhibitory concentration level against viral activity kept it from being repositioned as a treatment for COVID-19.
  • In October, Hyundai Bioscience already confirmed the solution to the problem of low bioavailability by revealing CP-COV03's Cmax level, which was 12.5 times higher than that of existing Niclosamide.

Hyundai Bioscience: A Korean bio-tech solves the bioavailability issue of Niclosamide

Retrieved on: 
Thursday, October 29, 2020
Anthelmintics, Chloroarenes, Salicylanilides, Niclosamide, Nitrobenzenes, Pesticides, Management of COVID-19, Bioavailability, Chemistry, Life sciences, Natural sciences

Hyundai Bioscience's parent company, CNPharm, has succeeded in dramatically increasing the bioavailability, or absorption rate, of Niclosamide into the blood system.

Key Points: 
  • Hyundai Bioscience's parent company, CNPharm, has succeeded in dramatically increasing the bioavailability, or absorption rate, of Niclosamide into the blood system.
  • As CNPharm has solved the low bioavailability issue of Niclosamide, the possibility of an early emergence of an oral COVID-19 treatment through drug repositioning has increased.
  • In April, Niclosamide, currently an anthelmintic, was selected by the Institute Pasteur Korea as the No.
  • Since the outbreak of the COVID-19 crisis, Niclosamide has been attracting much attention as a candidate drug due to its high effectiveness in treating COVID-19.

ANA Therapeutics Begins Phase 2/3 Clinical Trial of Proprietary Oral Niclosamide Formulation to Treat COVID-19

Retrieved on: 
Monday, October 26, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Anthelmintics, Chloroarenes, Niclosamide, Nitrobenzenes, Pesticides, Salicylanilides, Health, Medicine

ANA Therapeutics announced today that it has begun a multicenter, Phase 2/3 clinical trial to evaluate the safety and efficacy of its proprietary, oral niclosamide (ANA001) formulation for the treatment of patients with moderate COVID-19 disease.

Key Points: 
  • ANA Therapeutics announced today that it has begun a multicenter, Phase 2/3 clinical trial to evaluate the safety and efficacy of its proprietary, oral niclosamide (ANA001) formulation for the treatment of patients with moderate COVID-19 disease.
  • ANA Therapeutics refocused its business with the emergence of COVID-19 to utilize our expertise in niclosamide and drug formulation, said Akash Bakshi, Co-Founder and CEO of ANA Therapeutics.
  • ANA Therapeutics is a Silicon Valley-based biotech start-up developing a proprietary niclosamide formulation as a widely accessible antiviral treatment for patients with COVID-19.
  • ANA Therapeutics is the first Y Combinator portfolio company to initiate a Phase 2 clinical trial.

Danish biotech UNION adds program to prevent COVID-19 with intranasal delivery of niclosamide

Retrieved on: 
Wednesday, October 21, 2020
Medical specialties, RTT, Health, Chloroarenes, Niclosamide, Nitrobenzenes, Pesticides, Salicylanilides, Medicine, Coronavirus disease, Vaccine

HELLERUP, Denmark, Oct. 21, 2020 /PRNewswire/ -- UNION therapeutics A/S (UNION) announces expansion of the clinical pipeline with the addition of UNI91103 (intranasal niclosamide) to prevent COVID-19 and reduce the severity of the diseases among those already infected.

Key Points: 
  • HELLERUP, Denmark, Oct. 21, 2020 /PRNewswire/ -- UNION therapeutics A/S (UNION) announces expansion of the clinical pipeline with the addition of UNI91103 (intranasal niclosamide) to prevent COVID-19 and reduce the severity of the diseases among those already infected.
  • Several high-risk patient groups do not respond well to vaccination suggesting a persistent need for alternative prophylactic measures.
  • In response, UNION has expanded its clinical program for COVID-19 with a niclosamide based nasal spray (UNI91103) to prevent and alleviate infection among people at risk.
  • Furthermore, niclosamide has been demonstrated to prevent fatal outcomes in a murine model of COVID-19 when administered intranasally2.